English  |  正體中文  |  简体中文  |  Post-Print筆數 : 11 |  Items with full text/Total items : 88657/118248 (75%)
Visitors : 23503788      Online Users : 109
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://nccur.lib.nccu.edu.tw/handle/140.119/34306

    Title: 台灣發展醫藥研發服務產業之探討--以臨床試驗部分為例
    The Development of Contract Research Organizations in Taiwan:Case Study on Clinical Trials Management
    Authors: 洪錫娟
    Hung, Hsi-Chuan
    Contributors: 溫肇東
    Hung, Hsi-Chuan
    Keywords: 醫藥研發服務產業
    CRO (Contract Research Organization)
    Clinical Trial
    Date: 2004
    Issue Date: 2009-09-18 09:19:58 (UTC+8)
    Abstract: 昂貴的藥物研發成本,促使製藥生技產業的委外營運模式,以合約方式提供在藥物研發過程中專業化服務的產業,而近年來由於委外研發服務的高效率,已明顯縮短了新藥開發的時程;同時,在全球醫藥研發服務產業的市場中,約有超過七成的收益來自於臨床試驗服務;由此顯見醫藥研發服務產業中的臨床試驗部分的重要性。
    1. 以新藥研發價值鏈而言,台灣目前在每一個階段的工作均已佈局,其中又以臨床試驗階段最有潛力加入國際的競爭市場;長期而言,為追求醫藥產業最大的經濟效益,應強化國內的基礎研發工作,進而刺激與培養國內醫藥研發服務產業的能量。
    2. 產業政策的落實不能只談邏輯架構或觀念,應該設定明確的推動方案、目標與達成時間表,要推動產業必須貫徹以管理的觀念;同時也應加速業者與官方之間的溝通協調,其中包括藥政主管單位對於產業發展應由被動轉為積極主動的角色,另外,政府部門跨部會的整合也是相當重要的。
    3. 國內的全民健保制度涵蓋了所有醫療資源的運用,而健保制度的設計缺乏鼓勵預防與醫藥研發的投入的機制。因此建議應深入分析與探討健保對於產業的影響,進而能以更積極正面的態度促進製藥生技或醫藥研發服務產業的發展。
    4. 建議國內可以由政府與製藥產業界共同出資,成立具有公信力且目標明確的教育訓練組織,提供以實務為導向且有系統的在職教育,用以規劃與培植國家未來所需要的專業臨床試驗人才。
    5. 建議國內應就醫療院所執行臨床試驗相關作業訂定管理原則,包括臨床試驗贊助款的管理與運用規範、相關執行人員的權利義務等,藉由透明化的標準與明確的獎勵制度,提高醫師與醫院參與臨床試驗的動機;同時也應鼓勵醫院設立專責的臨床試驗辦公室,執行各項協調、整合與管理的工作,並促進與產業界間的互動。
    The cost of drug research and development has soared during the past years. And this compels pharmaceutical and biotechnology companies to look for new, smarter ways of running their businesses. One of their strategies is trying to accelerate drug development by outsourcing. The size of the outsourcing market for Contract Research Organizations (CROs) is rising. Clinical-trial operations hold over 70% of the revenue in the CRO industry.
    Competition in the CRO industry is extremely international in scope. The key issues for the catching-up company or country is to find their own niche. This study goes on to identify and profile the development of clinical trials and the CRO industry in Taiwan. It also seeks to identify ways of showcasing Taiwan as an Asia-Pacific Clinical Trail Service Center.
    There are several conclusions from this study:
    1. In the value chain of new drug discovery and development, the current status in Taiwan has the potential to join the international market by conducting the clinical trials. In the long term, we should consolidate our basic medical research to pursue the maximum benefit of biotechnology and pharmaceutical industry, and then to enhance the capability of CRO in Taiwan.
    2. The policy for improving industry must be set up after the explicit acting plans, goals and time schedule. It should go through with management, not just a structure or concept. We have to hasten the communication between industry and government. The medical legal authorities need to be more active. Ultimate integration of the functions of the related government departments is exceedingly important.
    3. The National Health Insurance (NHI) system covers all of the medical resources in Taiwan, but it lack for the incentive to encourage the medical research. It is recommended that NHI Program should probe into the impact of the biotechnology and pharmaceutical industry, and then try to revise it with more positive thinking.
    4. It is very important for Taiwan to improve the professional in clinical trials. Setting up a training center funded by both government and industries is strongly recommended. The organization will have the definite goals and accountability, and provide practical training and systematic continuing education.
    5. We need more regulating operations of clinical trials of hospitals in Taiwan. These operations should include the usage of the fees from sponsors, and the rights and responsibilities of all staff. We should set up a transparent standard and obviously encourage a mechanism to enhance the motivation of physicians and hospitals to participate in clinical trials. Hospitals should be encouraged to establish an independent office for clinical trials to perform all the details. This office will promote the interaction within the industries.
    Reference: 中文文獻
    1.Ann Neuer, Barry Miskin “QA for the Investigative Site: Building the right foundation is critical to success. Here's how to lay the groundwork for excellence.” Applied Clinical Trials, Nov 1, 2004.
    2.Applied Clinical Trials , “Education and training directory: A full listing of college and university courses, training classes, and other educational opportunities.” Applied Clinical Trials, Dec 1, 2004.
    3.Applied Clinical Trials , “Internet Resources: The following Web sites are focused on the professional and/or potential participant in clinical trials.” Applied Clinical Trials, Dec 1, 2004.
    4.CenterWatch , “CRO Market” CenterWatch, Vol.10, Issue 9, Sep, 2003, p.9-11
    5.Contract Pharma , “Top 15 CROs For Fiscal 2003”, Contract Pharma, May 2004, p.38
    6.Contract Pharma, “Now that Quintiles is going private, what’s next?” Contract Pharma Autumn Concerns, Sept 2003, p.28
    7.David Cavalla “The extended pharmaceutical enterprise.” Drug Discovery Today, Vol.8(6), March 2003. p.267-274
    8.Diana L. Anderson, “The Patient Recruitment Market” Applied Clinical Trials, Nov 2, 2003.
    9.DiMasi JA, Hansen RW, Grabowski HG, “The Price of Innovation: New Estimates of Drug□Development Costs.” Journal of Health Economics, 2003, Vol 22, p.151–185.
    10.DiMasi JA, Hansen RW, Grabowski HG, Lasagna L., “Cost of innovation in the pharmaceutical industry.” Journal of Health Economics, 1991, Vol 10, p.107-142
    11.Evan Gothard “Understanding Cost Drivers: Lessons Learned from Multiple Perspectives” Quintiles Presentations, 2002
    12.Faiz Kermani and Rebecca Gittins, “Finding the Next Asian Pharma Sensation” Contract Pharma, May 2004, p.54-59
    13.Food and Drug Administration. “CDER 2003 Report to the Nation: Improving Public Health Through Human Drugs”. Rockville, Maryland, 20857. 2004
    14.Food and Drug Administration. “Challenge and Opportunity on the Critical Path to New Medical Products.” March 2004.
    15.Food and Drug Administration. “FDA Announces Standard Format That Drug Sponsors Can Use to Submit Human Drug Clinical Trial Data.” July 2004.
    16.Frost & Sullivan “CRO industry coming under pressure,” (part of F&S’ Pharmaceuticals Monitor Service) 2003
    17.Graham Hughes, “The CRO Scene in 2003—A Brief Tour.” European Pharmaceutical Contractor, Summer 2004, p.8-10
    18.Hansen RW, “The pharmaceutical development process: estimate of current development costs and times and the effect of regulatory changes.” 1979, Lexington Books, Lexington, MA, p.151-187.
    19.Janice M. Reichert, “Trends in development and approval times for new therapeutics in the united states.” Drug Discovery, Sep 2003, Vol 2, p.695-702.
    20.Jill Weschler, “Clinical Trial Listings and Results Go Public” Applied Clinical Trials, Oct 1, 2004.
    21.Kathleen B. Drennan, “Patient recruitment: the costly and growing bottleneck in drug development” Drug Discovery Today, February 1 2002, Vol 7, Issue 3, P.167-170.
    22.Kenneth A. Getz and John R. Vogel, "Achieving Results with CROs: Their Evolving Role in Clinical Development," Applied Clinical Trials, April 1995, 32-38.
    23.Mary Jo Lamberti, “Going Global” Applied Clinical Trials, Jun 1, 2004
    24.Michael A. Martorell, “Consolidation in Outsourcing, A look back at 2003 and a look ahead to 2004,” Contract Pharma, Jan 2004.
    25.OPPI—Monitor Group Collaboration, “Outsourcing Opportunities in Indian Pharmaceutical Industry.” Sep, 2003.
    26.Peter Lissinger, “Outsourcing: Do it Well or Not at All,” Drug Discovery & Development, March 2004, Vol.7 Issue 3, P.15
    27.Philip J. Holt, James E. Lodge, “Merging Collaboration and Technology: The Virtual Research Organization” Applied Clinical Trials, Oct 1, 2003.
    28.Richard A. Retting, “The Industrialization of Clinical Research,” Health Affairs 19, no.2 (2000): 129-146
    29.Sarah W. Madley, “Snapshot: The CRO Industry Today, Industry strengthens relationships with sponsors, learns the benefits of flexibility and moves more trials out of the developed world.” Contract Pharma, May 2004, Vol 6, No. 4, p.40-47
    30.Simon Frantz, “Why are clinical costs so high?” Nature reviews drug discovery, Nov 2003, Vol 2, p.851-852
    31.Solomon Nwaka and Robert G. Ridley, “Virtual drug discovery and development for neglected diseases through public—private partnerships.” Nature Review Drug Discovery, Nov. 2003, Vol 2, p.919-928
    32.Steven Heffne, “Beyond The CRO : Other players search for their slice of the drug development pie.” Contract Pharma, 2004.03
    33.Terumasa Hirai, “Communication between the sponsor and CRO - The contract laboratory perspective” The Quality Assurance Journal, June 1998, Vol 3, Issue 2, P.51-55.
    34.The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) , “The Value and Benefits of ICH to Industry” 2000
    35.Toby Jane Hindin, “Looking Back, Moving Forward: A CRO Retrospective”, Applied Clinical Trials, Aug 2, 2004
    36.V.E.K.M. van de Walle “CRO—SMO: Partners in Business or Business Partners?” Monitor, Spring 2002, p.25-28
    1.Applied Clinical Trials, http://www.actmagazine.com/appliedclinicaltrials/
    2.Contract Pharma, http://www.contractpharma.com/
    3.PhRMA, “Updated Principles For Conduct Of Clinical Trials And Communication Of Clinical Trial Results,” http://www.phrma.org/mediaroom/press/releases/30.06.2004.427.cfm
    4.Quintiles Transnational Corp., Form 10-K (http://www.quintiles.com) Dec. 2003
    5.R&D Directions Staff, “Prospects are good.” http://www.rddirections.com/magazines/randd/view.cfm?articleID=1279
    6.The U.S. Food and Drug Administration (FDA) website, http://www.fda.gov
    7.TheStreet.com, “Cashing in on privatization,” http://www.thestreet.com/markets/rebeccabyrne/10088838.html
    8.Triangle Business Journal, “In depth: largest triangle deals of 2003,” http://www.bizjournals.com/triangle/stories/2004/02/09/focus1.html
    9.Trimanos Corp. website, http://trimanos.com/resources/stakehoders/index.html
    10.Tufts Center for the Study of Drug Development ,http://csdd.tufts.edu/
    Description: 碩士
    Source URI: http://thesis.lib.nccu.edu.tw/record/#G0090359026
    Data Type: thesis
    Appears in Collections:[科技管理研究所] 學位論文

    Files in This Item:

    File Description SizeFormat
    35902602.pdf18KbAdobe PDF1183View/Open
    35902603.pdf29KbAdobe PDF1088View/Open
    35902604.pdf146KbAdobe PDF1224View/Open
    35902605.pdf70KbAdobe PDF1488View/Open
    35902606.pdf548KbAdobe PDF1771View/Open
    35902607.pdf277KbAdobe PDF1575View/Open
    35902608.pdf212KbAdobe PDF3311View/Open
    35902609.pdf182KbAdobe PDF4615View/Open
    35902610.pdf110KbAdobe PDF1759View/Open
    35902611.pdf42KbAdobe PDF1039View/Open
    35902612.pdf45KbAdobe PDF1209View/Open
    35902613.pdf15KbAdobe PDF869View/Open

    All items in 政大典藏 are protected by copyright, with all rights reserved.

    社群 sharing

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback